We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

160 hedge funds and large institutions have $2.2B invested in Portola Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 71 increasing their positions, 44 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,619% more call options, than puts

Call options by funds: $3.95M | Put options by funds: $230K

61% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 44

21% more capital invested

Capital invested by funds: $1.82B → $2.2B (+$388M)

0% more funds holding

Funds holding: 160160 (0)

0% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 24

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

Holders
160
Holders Change
Holders Change %
0%
% of All Funds
4.31%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.08%
New
24
Increased
71
Reduced
44
Closed
24
Calls
$3.95M
Puts
$230K
Net Calls
+$3.72M
Net Calls Change
+$2.95M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$311M +$30.8M +764,530 +13%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$284M +$1.57M +39,000 +0.6%
Temasek Holdings
3
Temasek Holdings
Singapore
$266M
Vanguard Group
4
Vanguard Group
Pennsylvania
$136M +$21.9M +543,731 +22%
BFA
5
BlackRock Fund Advisors
California
$81.9M -$117K -2,901 -0.2%
Franklin Resources
6
Franklin Resources
California
$70.3M +$1.78M +44,300 +3%
EAM
7
Eagle Asset Management
Florida
$67M +$216K +5,368 +0.4%
State Street
8
State Street
Massachusetts
$59.6M +$2.06M +51,201 +4%
Citadel Advisors
9
Citadel Advisors
Florida
$57.9M +$12.2M +303,618 +31%
MAM
10
MPM Asset Management
Massachusetts
$55.6M
SAM
11
Sectoral Asset Management
Quebec, Canada
$53.3M +$257K +6,400 +0.6%
BIT
12
BlackRock Institutional Trust
California
$44.2M +$5.71M +141,818 +17%
JP Morgan Chase
13
JP Morgan Chase
New York
$42.2M -$853K -21,212 -2%
O
14
OrbiMed
New York
$38.7M
Jennison Associates
15
Jennison Associates
New York
$29.6M +$263K +6,543 +1%
Northern Trust
16
Northern Trust
Illinois
$24.9M +$1.54M +38,401 +8%
PC
17
Polar Capital
United Kingdom
$23.6M -$2.01M -50,021 -9%
CAM
18
Cormorant Asset Management
Massachusetts
$22.8M -$3M -74,500 -13%
HCMT
19
Highland Capital Management (Texas)
Texas
$20.6M +$14.3M +356,599 +375%
EA
20
Emerald Advisers
Pennsylvania
$19.7M -$29.5K -734 -0.2%
Millennium Management
21
Millennium Management
New York
$19.1M -$11.6M -287,310 -41%
EAM
22
Eventide Asset Management
Massachusetts
$18.5M
T. Rowe Price Associates
23
T. Rowe Price Associates
Maryland
$17.8M -$736K -18,300 -4%
FAM
24
Fred Alger Management
New York
$17.8M -$3.74M -93,087 -19%
Marshall Wace
25
Marshall Wace
United Kingdom
$17.2M +$3.27M +81,180 +27%

PTLA Hedge Fund Activity: Q2 2015 in Review

160 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q2 2015, worth a combined $2.2B — up 21% from $1.82B a quarter earlier.

Fund positioning in PTLA was balanced in Q2 2015: 24 funds opened new positions, 24 closed out, 71 added to existing stakes and 44 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $30.8M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $37.2M sold.

  • 160 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q2 2015, unchanged from Q1 2015.
  • Funds reported $2.2B of Portola Pharmaceuticals, Inc. stock for Q2 2015, up 21% quarter-over-quarter.
  • 24 funds opened new Portola Pharmaceuticals, Inc. positions in Q2 2015 and 24 closed out, a net change of 0 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q2 2015 was Wellington Management Group, an estimated $30.8M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q2 2015 was Scopia Capital Management, an estimated $37.2M sold.

Based on aggregated 13F filings for Q2 2015.